Anti-amyloid Alzheimer's drugs show no clinically meaningful effect

medicalxpress - Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new review in the Cochrane Database of Systematic Reviews has found.

AI Summary: A major review concludes anti-amyloid Alzheimer’s medications show no clinically meaningful effect on patients’ cognition or daily function, prompting renewed debate about drug approvals, prescribing and research priorities. The analysis calls for careful reassessment of treatment value, clearer communication to patients and tighter scrutiny of future trials.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #researchfunding #clinicaltrials

Anti-amyloid drugs fall short: little benefit, safety risks (5)
New biomarkers and imaging reshape Alzheimer’s diagnosis timing (3)
Social and care issues: loneliness, memory and treatment decisions (2)
All Other Stories

Anti-amyloid drugs fall short: little benefit, safety risks

Cochrane review dismissing amyloid drugs draws immediate backlash

6 wks / endpoints / Ryan Cross

Much-hyped Alzheimer's drugs removed amyloid yet brought no meaningful gains over 18 months

6 wks / medicalxpress

'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests

6 wks / bbc

Anti-amyloid Alzheimer's drugs show no clinically meaningful effect

6 wks / medicalxpress

Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness

6 wks / nytimes / Pam Belluck

New Bill Seeks to Lower Out-of-Pocket Drug Costs

Marissa Plescia / medcitynews - Rep. Greg Murphy introduced a bill that would require out-of-pocket prescription drug spending to count toward patients’ deductibles and out-of-pocket maximums regardless of where the drugs are purchased.The post New Bill Seeks to Lower Out-of-Pocket Drug…

AI Summary: Lawmakers introduced legislation to reduce out‑of‑pocket drug costs by allowing patients' direct drug purchases to count toward their insurance deductibles. The proposal aims to ease financial strain for people buying costly medications out‑of‑pocket, but would require insurers and pharmacy systems to change longstanding accounting and benefits practices.

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #healthcarefinance #pricetransparency #healthdisparities

An Arm and a Leg: The Accidental Architect of America’s Drug Patent Problem

5 wks / kffhealthnews / Dan Weissmann

45 state attorneys general back PBM transparency

6 wks / beckershospitalreview / Ella Jeffries

Stakeholders urge Labor Department to finalize PBM transparency rule

6 wks / healthcaredive / Rebecca Pifer Parduhn

New Bill Seeks to Lower Out-of-Pocket Drug Costs

6 wks / medcitynews / Marissa Plescia

House eyes bill to allow drug expenditures to count toward insurance deductibles

6 wks / beckershospitalreview / Mariah Taylor

Bill would force payers to apply DTC drug purchases to patient deductibles